Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

Bruton tyrosine kinase (Btk) has a well-defined role in B-cell development, whereas its expression in osteoclasts (OCs) further suggests a role in osteoclastogenesis. Here we investigated effects of PCI-32765, an oral and selective Btk inhibitor, on osteoclastogenesis as well as on multiple myeloma...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Tai, Yu-Tzu, Chang, Betty Y., Kong, Sun-Young, Fulciniti, Mariateresa, Yang, Guang, Calle, Yolanda, Hu, Yiguo, Lin, Jianhong, Zhao, Jian-Jun, Cagnetta, Antonia, Cea, Michele, Sellitto, Michael A., Zhong, Mike Y., Wang, Qiuju, Acharya, Chirag, Carrasco, Daniel R., Buggy, Joseph J., Elias, Laurence, Treon, Steven P., Matsui, William, Richardson, Paul, Munshi, Nikhil C., Anderson, Kenneth C.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2012
Soggetti:
Lymphoid Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3433091/
https://ncbi.nlm.nih.gov/pubmed/22689860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-12-396853
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi